Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2008-6-10
pubmed:abstractText
Exploration for new MDR-modulator utilizing tetrahydroisoquinoline as scaffold disclosed 6,7-dimethoxy-1-(3,4-dimethoxy)benzyl-2-(N-n-octyl-N'-cyano)guanyl-1,2,3,4-tetrahydroisoquinoline (7) as a readily accessible medicinal lead. Compound 7 possessed potent MDR reversal activity in the range of the reference compound verapamil, and had not cardiovascular activity compared to verapamil.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1464-3405
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3652-5
pubmed:meshHeading
pubmed-meshheading:18502125-Amidines, pubmed-meshheading:18502125-Animals, pubmed-meshheading:18502125-Anti-Arrhythmia Agents, pubmed-meshheading:18502125-Antineoplastic Agents, pubmed-meshheading:18502125-Arrhythmias, Cardiac, pubmed-meshheading:18502125-Cell Line, Tumor, pubmed-meshheading:18502125-Cell Proliferation, pubmed-meshheading:18502125-Dose-Response Relationship, Drug, pubmed-meshheading:18502125-Drug Design, pubmed-meshheading:18502125-Drug Resistance, Multiple, pubmed-meshheading:18502125-Drug Resistance, Neoplasm, pubmed-meshheading:18502125-Drug Screening Assays, Antitumor, pubmed-meshheading:18502125-Humans, pubmed-meshheading:18502125-Isoquinolines, pubmed-meshheading:18502125-Mice, pubmed-meshheading:18502125-Mice, Nude, pubmed-meshheading:18502125-Myocardial Contraction, pubmed-meshheading:18502125-Neoplasms, pubmed-meshheading:18502125-Rats, pubmed-meshheading:18502125-Rats, Sprague-Dawley, pubmed-meshheading:18502125-Structure-Activity Relationship, pubmed-meshheading:18502125-Tetrahydroisoquinolines, pubmed-meshheading:18502125-Time Factors, pubmed-meshheading:18502125-Verapamil
pubmed:year
2008
pubmed:articleTitle
Design and synthesis of tetrahydroisoquinoline derivatives as potential multidrug resistance reversal agents in cancer.
pubmed:affiliation
Center of Drug Discovery, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, Jiangsu 210009, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't